Member of the Board of Directors
Jörn Aldag leads the board of Molecular Partners. He is CEO of Hookipa Biotech AG, Vienna, a company developing innovative active immunization therapies for infectious diseases and immuno-oncology. Previously, Mr. Aldag was the CEO of Nasdaq-listed uniQure N.V (2009-2015), a company pioneering adeno-associated virus based gene therapy. Under his leadership, uniQure received the first ever approval of a gene therapy product by the European Medicines Agency, built a broad pipeline of gene therapy products across several disease areas, obtained approximately $200 million through its NASDAQ-listing and follow-on, and closed a multi-billion dollar collaboration in cardiovascular gene therapy. Previously, Mr. Aldag was President and CEO of Evotec AG (1997-2008). At Evotec AG, he designed many alliances with leading pharma and biotech companies, listed the company on the Frankfurt Stock Exchange and Nasdaq and managed the acquisition of LSE-listed Oxford Asymmetry and Nasdaq-listed Renovis Inc. Mr. Aldag is also a co-founder of G7 Therapeutics, Zurich, a GPCR company, successfully divested to Heptares in 2016. He is also a board member of Unum Therapeutics, which is developing next-gen immuno-oncology therapies. Mr. Aldag holds business degrees from the European Business School and Harvard Business School (AMP).